SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that the Board of Directors has appointed Mr. Gregg Williams as Chairman of the Board, effective immediately. Mr. Williams, a current member of the Board of Directors of Second Sight and the Company’s largest
Category: Business
BioTime Reports Fourth Quarter and Fiscal 2017 Results
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017. “2017 was a successful year for BioTime, capped by our recent European CE Mark submission of Renevia® and approval by the DSMB to proceed with the initiation of Cohort 4 of the OpRegen® clinical trial,” said Adi Mohanty, Co-Chief Executive Officer of BioTime.
Asia-Pacific Uveitis Therapeutics Markets 2018-2023 – Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Uveitis Therapeutics in Asia-Pacific Markets to 2023 – Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market” report has been added to ResearchAndMarkets.com’s offering. The Asia…
Back of the Eye Disorders, Featuring a Steadily Growing Pipeline, Likely to Witness 7.9% Annualized Growth, Predicts Roots Analysis
LONDON–(BUSINESS WIRE)–#BackoftheEyeDisorders–Back of the Eye Disorders, featuring a steadily growing pipeline, likely to witness 7.9% annualized growth, predicts Roots Analysis.
SeniorWell Expands Leadership Team with Executive Hire
CHICAGO–(BUSINESS WIRE)–SeniorWell Expands Leadership Team with Executive Hire, New CEO will expand the company’s footprint and optimize patient experience
Resumen: EyeArt™, el software de detección de retinopatía diabética basado en la inteligencia artificial de Eyenuk Inc. ha sido probado con el dispositivo portátil de imágenes vinculado a un teléfono inteligente en un nuevo estudio que señala el potencial …
LOS ÁNGELES–(BUSINESS WIRE)–EyeArt™, el software de detección de retinopatía diabética basado en la inteligencia artificial de Eyenuk Inc. ha sido probado con el dispositivo portátil de imágenes vinculado a un teléfono inteligente en un nuevo estudio que señala el potencial para la detección retiniana masiva altamente sensible y rentable Eyenuk, Inc., líder en el desarrollo de soluciones avanzadas basadas en inteligencia artificial (IA) clínicamente probadas para la identificación de enfermed
EyeArt™, le logiciel de dépistage de la rétinopathie diabétique à base d’IA d’Eyenuk Inc., a été testé sur un dispositif d’imagerie portable fonctionnant à partir d’un smartphone dans le cadre d’une étude indiquant la possibilité d’un dépistage…
LOS ANGELES–(BUSINESS WIRE)–EyeArt™, le logiciel de dépistage de la rétinopathie diabétique à base d’IA d’Eyenuk Inc., a été testé sur un dispositif d’imagerie portable fonctionnant à partir d’un smartphone dans le cadre d’une étude indiquant la possibilité d’un dépistage rétinien de masse hautement sensible et offrant un bon rapport coût/efficacité Eyenuk, Inc., un leader dans le développement de solutions avancées et étayées cliniquement à base d’intelligence artificielle (IA) pour l’identi
KI-gestützte Software EyeArt™ von Eyenuk Inc. für Screening auf diabetische Retinopathie in neuer Studie mit tragbarem, smartphonegestütztem Bildgebungsgerät getestet – legt Potential für hochempfindliche, aber kosteneffektive Reihen-Netzhaut-Screenings …
LOS ANGELES–(BUSINESS WIRE)–KI-gestützte Software EyeArt™ von Eyenuk Inc. für Screening auf diabetische Retinopathie in neuer Studie mit tragbarem, smartphonegestütztem Bildgebungsgerät getestet – legt Potential für hochempfindliche, aber kosteneffektive Reihen-Netzhaut-Screenings nahe Eyenuk, Inc., ein führender Entwickler moderner, klinisch gestützter, für künstliche Intelligenz (KI) kompatibler Lösungen zur Erkennung von Erkrankungen über die Analyse von Netzhautbildern, hat heute die Verö
Riassunto: EyeArt™, il software per lo screening della retinopatia diabetica basato sull’intelligenza artificiale sviluppato da Eyenuk Inc., è stato collaudato con un dispositivo di imaging basato su smartphone portatile in un nuovo studio che ne ha …
LOS ANGELES–(BUSINESS WIRE)–EyeArt™, il software per lo screening della retinopatia diabetica basato sull’intelligenza artificiale sviluppato da Eyenuk Inc., è stato collaudato con un dispositivo di imaging basato su smartphone portatile in un nuovo studio che ne ha dimostrato il potenziale quale strumento di screening di massa della retinopatia altamente sensibile ed economico Eyenuk, Inc., una prestigiosa società impegnata nello sviluppo di soluzioni avanzate basate sull’intelligenza artifi
Global Retinopathy Partnering Directory 2012 to 2018 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Retinopathy Partnering 2012 to 2018” report has been added to ResearchAndMarkets.com’s offering. The Global Retinopathy Partnering Terms and Agreements since 2012 report provides understanding and access to partneri…
Global Dry Eye Partnering Directory 2012-2018 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Eye Partnering 2012 to 2018” report has been added to ResearchAndMarkets.com’s offering. The Global Dry Eye Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals…
Gene Therapy for Age-related Macular Degeneration – Pipeline Analysis | Technavio
LONDON–(BUSINESS WIRE)–#AMD–Technavio has announced its market research report on gene therapy for age-related macular degeneration from 2018-2022.
Allergic Conjunctivitis Pipeline Highlights – 2017 Update – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Allergic Conjunctivitis Pipeline Highlights – 2017 Update” drug pipelines has been added to ResearchAndMarkets.com’s offering. Allergic Conjunctivitis Pipeline Highlights – 2017 Update, provides most up-to-date information…
Second Sight Medical Products, Inc. to Present at the B. Riley & Co. China Healthcare Investment Partnering Symposium
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today announced that Will McGuire, President and Chief Executive Officer, will present at the B. Riley & Co. China Healthcare Investment Partnering Symposium as follows: Date: Friday, March 16, 2018Presentation Time: 11:
Second Sight Reports Fourth Quarter and Full Year 2017 Financial Results
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vis…
2017 Glaucoma Pipeline Highlights Update – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Glaucoma Pipeline Highlights – 2017 Update” drug pipelines has been added to ResearchAndMarkets.com’s offering. Glaucoma Pipeline Highlights – 2017 Update, provides most up-to-date information on key pipeline products in t…
Retinitis Pigmentosa: Global Therapeutics Pipeline Analysis Report 2017 with jCyte, Dompe Farmaceutici, ProRetina Therapeutics and Recursion Pharmaceuticals Dominating – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinitis Pigmentosa Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments” report has been added to ResearchAndMarkets.com’s offering. The study analyzed that the retinitis pigmentosa therapeutics pipeline comprises approximately 38 drug candidates in different stages of development. Orphan drug designations from the regulatory bodies such as Food and Drug Administration (FDA), European M
Latest MVI Research Tests Eyewear Brands Among Wealthy Millennials
AUSTIN, Texas–(BUSINESS WIRE)–#Coach–Latest MVI Research Tests Eyewear Brands Among Wealthy Millennials. Ray-Ban still the king but other brands also strong with young luxury consumers.
BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the fourth cohort for the ongoing OpRegen® clinical trial. The DSMB is an independent group of medical experts closely monitoring the Phase I/IIa OpRegen® clinical trial. The approval was based on the continued safety observed throughout the fir
Aerie Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…